Skip to main content
SpringerLink
Log in

Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Aims

We determined adalimumab utilisation and associated drug costs in patients with ulcerative colitis (UC), focusing on patients requiring dose escalation.

Methods

The retrospective cohort study analysed the de-identified prescription data of the Arvato Health Analytics (Munich, Germany) database (2010–2015) in adult UC patients undergoing adalimumab therapy.

Results

A total of 154 patients were newly treated with adalimumab (average 39.6 years, 53% females), with a mean dose of 2.93 mg/day. Within 12 months, 69 patients (45%) received a dose increase of > 50% (doubled dose in 48 patients; 32%), with the escalation reported at 169.3 ± 99.3 days. A subsequent dose de-escalation to the standard dose occurred in 50 (32%) of patients that initially had a dose increase of > 50% (after 94.7 ± 49.6 days). Direct drug costs were 28,846 € in the overall study population, 24,934 € in patients on standard dose, 36,094 € in patients with dose increase, and 32,742 € in patients with increase and subsequent decrease.

Conclusion

Dose escalation occurred frequently, and in one third of patients the dose was at least doubled. Dose escalations were associated with substantial increases in direct drug costs. Dose escalation of adalimumab can severely affect both the health care system and the drug budget of the physician. It needs to be considered that other biologic medications may constitute a more cost-effective alternative.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ordas, I., Eckmann, L., Talamini, M., Baumgart, D.C., Sandborn, W.J.: Ulcerative colitis. Lancet 380(9853), 1606–1619 (2012)

    Article  Google Scholar 

  2. Kornbluth, A., Sachar, D.B.: Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 105(3), 501–523 (2010)

    Article  PubMed  Google Scholar 

  3. Dignass, A., Van Assche, G., Lindsay, J.O., Lemann, M., Soderholm, J., Colombel, J.F., et al.: The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J. Crohns Colitis 4(1), 28–62 (2010)

    Article  CAS  PubMed  Google Scholar 

  4. Hindryckx, P., Baert, F., Hart, A., Magro, F., Armuzzi, A., Peyrin-Biroulet, L.: Clinical trials in ulcerative colitis: a historical perspective. J. Crohns Colitis 9(7), 580–588 (2015)

    Article  PubMed  Google Scholar 

  5. Deutsche Gesellschaft für Gastroenterologie, Verdauungs-und Stoffwechselkrankheiten (DGVS). Colitis ulcerosa: Diagnostik und Therapie (no. 021-009). Issued in 2009, currently under revision. http://www.awmf.org/leitlinien/detail/ll/021-009.html. Accessed 24 July 2017

  6. Dignass, A., Preiss, J.C., Aust, D.E., Autschbach, F., Ballauff, A., Barretton, G., et al.: Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z. Gastroenterol. 49(9), 1276–1341 (2011)

    Article  CAS  PubMed  Google Scholar 

  7. Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., et al.: Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management. J. Crohns Colitis 11(7), 769–784 (2017)

    Article  PubMed  Google Scholar 

  8. Decision Resources Group (DRG).: Immune and inflammatory disorders. Ulcerative colitis. Analyzing and forecasting the commercial outlook for drugs on the market and in research and development. Report updated in September 2015. Decision Resources Burlington, MA, USA

  9. European Medicines Agency (EMA).: Humira EMEA/H/C/000481-II/0156. Summary of product characteristics (SPC). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000481/human_med_000822.jsp&mid=WC0b01ac058001d124. Accessed 3 Dec 2016

  10. Armuzzi, A., Pugliese, D., Nardone, O.M., Guidi, L.: Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. Drug Des. Dev. Ther. 7, 289–296 (2013)

    Article  CAS  Google Scholar 

  11. Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., et al.: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1), 46–54 (2012). (quiz e30)

    Article  Google Scholar 

  12. Wolf, D., D’Haens, G., Sandborn, W.J., Colombel, J.F., Van Assche, G., Robinson, A.M., et al.: Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment. Pharmacol. Ther. 40(5), 486–497 (2014)

    CAS  PubMed  Google Scholar 

  13. Summary of product characteristics (SPC)/prescribing information adalimumab (Humira 40 mg). Manufacturer AbbVie, UK, June 2016. http://www.fachinfo.de. Accessed 3 Dec 2016

  14. IMS Health.: Prescriptions and market share of biologics in gastroenterology. Internal data IMS Sell NI. (2017)

  15. IMS Health.: Share of TNF α inhibitors in various gastrointestinal diseases in Germany. Unpublished report (2016)

  16. Black, C.M., Yu, E., McCann, E., Kachroo, S.: Dose escalation and healthcare resource use among ulcerative colitis patients treated with adalimumab in English hospitals: an analysis of real-world data. PLoS ONE 11(2), e0149692 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Salomonsson, S., Soderberg, J., Alenadaf, K., Ljung, T.: Dose escalation among ulcerative colitis patients treated with adalimumab in Sweden. Value Health 18(7), A633 (2015)

    Article  Google Scholar 

  18. Motheral, B., Brooks, J., Clark, M.A., Crown, W.H., Davey, P., Hutchins, D., et al.: A checklist for retrospective database studies—report of the ISPOR Task Force on Retrospective Databases. Value Health 6(2), 90–97 (2003)

    Article  PubMed  Google Scholar 

  19. Arbeitsgruppe Erhebung und Nutzung von Sekundärdaten der Deutschen Gesellschaft für Sozialmedizin und Prävention, Arbeitsgruppe Epidemiologische Methoden der Deutschen Gesellschaft für Epidemiologie, Deutsche Gesellschaft für Medizinische Informatik Biometrie und Epidemiologie, Deutsche Gesellschaft für Sozialmedizin und Prävention. Good practice of secondary data analysis, first revision. Gesundheitswesen 70(1), 54–60 (2008) (original in German)

  20. Drösler, S., Hasford, J., Kurth, B.-M., Schaefer, M., Wasem, J., Wille, E.: Evaluationsbericht zum Jahresausgleich 2009 im Risikostrukturausgleich. https://www.bundesgesundheitsministerium.de/fileadmin/dateien/Publikationen/Gesundheit/Forschungsberichte/Evaluationsbericht_zum_Jahresausgleich.pdf. Accessed 6 Nov 2016

  21. Swart, E., Bitzer, E.M., Gothe, H., Harling, M., Hoffmann, F., Horenkamp-Sonntag, D., et al.: [A consensus German reporting standard for secondary data analyses, Version 2 (STROSA-STandardisierte BerichtsROutine fur SekundardatenAnalysen)]. Gesundheitswesen 78(S01), e161 (2016)

  22. Schwabe, U., Paffrath, D.: Arzneiverordnungs-Report 2016: Aktuelle Daten, Kosten, Trends und Kommentare. Kapitel 3 Neue Arzneimittel, Seite 57: Springer Berlin Heidelberg

  23. R Development Core Team: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria (2017)

  24. Armuzzi, A., Biancone, L., Daperno, M., Coli, A., Pugliese, D., Annese, V., et al.: Adalimumab in active ulcerative colitis: a “real-life” observational study. Dig. Liver Dis. 45(9), 738–743 (2013)

    Article  CAS  PubMed  Google Scholar 

  25. Afif, W., Leighton, J.A., Hanauer, S.B., Loftus Jr., E.V., Faubion, W.A., Pardi, D.S., et al.: Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm. Bowel Dis. 15(9), 1302–1307 (2009)

    Article  PubMed  Google Scholar 

  26. Gies, N., Kroeker, K.I., Wong, K., Fedorak, R.N.: Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment. Pharmacol. Ther. 32(4), 522–528 (2010)

    Article  CAS  PubMed  Google Scholar 

  27. Oussalah, A., Laclotte, C., Chevaux, J.B., Bensenane, M., Babouri, A., Serre, A.A., et al.: Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment. Pharmacol. Ther. 28(8), 966–972 (2008)

    Article  CAS  PubMed  Google Scholar 

  28. Baki, E., Zwickel, P., Zawierucha, A., Ehehalt, R., Gotthardt, D., Stremmel, W., et al.: Real-life outcome of anti-tumor necrosis factor alpha in the ambulatory treatment of ulcerative colitis. World J. Gastroenterol. 21(11), 3282–3290 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sandborn, W.J., van Assche, G., Reinisch, W., Colombel, J.F., D’Haens, G., Wolf, D.C., et al.: Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2), 257–265 (2012)

    Article  CAS  PubMed  Google Scholar 

  30. Colombel, J.F., Sandborn, W.J., Ghosh, S., Wolf, D.C., Panaccione, R., Feagan, B., et al.: Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am. J. Gastroenterol. 109(11), 1771–1780 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Beschluss des Gemeinsamen Bundesausschusses (G-BA) über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII—Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V—Vedolizumab. 8 Jan 2015. BAnz AT 9 (2015)

  32. Reinisch, W., Sandborn, W.J., Hommes, D.W., D’Haens, G., Hanauer, S., Schreiber, S., et al.: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60(6), 780–787 (2011)

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was funded by MSD Sharp & Dohme GmbH, Haar, Germany.

Author information

Authors and Affiliations

  1. Market Access, MSD Sharp & Dohme GmbH, Haar, Germany

    Bernadette Pöllinger, Wolfgang Schmidt & Heidi Imhoff

  2. Gesundheitsforen Leipzig GmbH, Leipzig, Germany

    Anna Seiffert

  3. Versorgungsmanagement an der Friedrich-Alexander-Universität Erlangen-Nürnberg, Raum 5.255, Lange Gasse 20, 90403, Nuremberg, Germany

    Martin Emmert

Authors
  1. Bernadette Pöllinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Seiffert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heidi Imhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin Emmert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Emmert.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pöllinger, B., Schmidt, W., Seiffert, A. et al. Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany. Eur J Health Econ 20, 195–203 (2019). https://doi.org/10.1007/s10198-017-0953-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-017-0953-z

Keywords

JEL Classification

Search

Navigation